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ABSTRACT
It is challenging to identify at diagnosis those patients with early oral squamous 
cell carcinoma (OSCC), who have a poor prognosis and those that have a high risk 
of harboring occult lymph node metastases. The aim of this study was to develop a 
standardized and objective digital scoring method to evaluate the predictive value of 
tumor budding. We developed a semi-automated image-analysis algorithm, Digital 
Tumor Bud Count (DTBC), to evaluate tumor budding. The algorithm was tested in 
222 consecutive patients with early-stage OSCC and major endpoints were overall 
(OS) and progression free survival (PFS). We subsequently constructed and cross-
validated a binary logistic regression model and evaluated its clinical utility by 
decision curve analysis. A high DTBC was an independent predictor of both poor OS 
and PFS in a multivariate Cox regression model. The logistic regression model was 
able to identify patients with occult lymph node metastases with an area under the 
curve (AUC) of 0.83 (95% CI: 0.78–0.89, P <0.001) and a 10-fold cross-validated 
AUC of 0.79. Compared to other known histopathological risk factors, the DTBC had a 
higher diagnostic accuracy. The proposed, novel risk model could be used as a guide 
to identify patients who would benefit from an up-front neck dissection.
INTRODUCTION
The world-wide incidence of oral squamous cell 
carcinoma (OSCC) is estimated to be greater than 300,000 
new cases a year [1]. OSCC survival and treatment depend 
largely upon the clinical tumor-node-metastasis (TNM) 
classification, and 5-year survival in stage I–II OSCC is 
approximately 80% [2, 3]. Up to 30% of OSCC patients 
with a clinical N0 (cN0) neck can be demonstrated to 
harbor occult lymph node metastases when performing 
a sentinel lymph node biopsy (SNB). The discovery of 
a single micro- or macroscopic lymph node metastasis 
confers a poorer prognosis [3, 4]. Identifying which 
patients with early-stage OSCC who have a high risk of 
harboring occult lymph metastases is of great clinical 
importance, since these patients would benefit from 
therapeutic neck dissection [5].
Several tumor features have been proposed to 
aid in predicting which patients have occult lymph 
node metastases at diagnosis, such as gene expression 
signatures [6–8], tumor depth [3, 9–11] and “worst pattern 
of invasion” [12]. However, none of these has been 
implemented consistently in routine clinical practice, some 
because of a lack of validation [7, 8] and/or a low cost-
benefit ratio [6], and others because the complex and time-
consuming scoring systems [12] are difficult to implement 
in a busy pathology department.
The term “tumor budding” was coined by Hase et al 
over 20 years ago, and it is currently defined as isolated 
clusters of up to five tumor cells [13, 14]. A high tumor 
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bud count at the invasive front have been linked to a 
poorer prognosis and to a high risk of metastases in several 
cancer types, including OSCC [15–20]. Despite efforts 
to standardize and simplify the scoring of tumor buds, 
scoring remains time consuming, and a certain degree of 
subjective interpretation remains that results in relatively 
high inter- and intraobserver variability. Our research 
group has previously shown the predictive potential of 
evaluating tumor budding digitally in a mixed group of 
patients with OSCC who were primarily in an advanced 
stage [17]. We therefore propose the use of a quantitative, 
semi-automatic digital image analysis algorithm that 
would standardize the evaluation of tumor buds in clinical 
T1-T2N0M0 OSCC. We call this measure of tumor 
dissociation the Digital Tumor Bud Count (DTBC).
The purpose of this study was thus to evaluate the 
performance of the DTBC in predicting prognosis and to 
determine whether the DTBC would be clinically useful 
in identifying patients with occult lymph node metastases. 
A clinically useful, reliable, pathological scoring system 
to identify OSCC patients who are most likely to have 
poor survival therefore has great clinical importance and 
applicability.
RESULTS
Clinical and pathological characteristics
Table 1 summarizes the clinicopathological 
characteristics of the included subjects as obtained from 
surgery and patients hospital records. The median age of 
the included patients was 64 years (range: 30–95), and the 
median length of follow-up for those alive at last follow-
up was 3.0 years (range: 0.79–7.6 years). The majority 
of tumors were clinical T1 (cT1) (65%), and 34% had 
regional disease (Table 1).
Digital image analysis of tumor budding
Using digital image analysis, we obtained an 
objective measure of the degree of tumor dissociation, i.e. 
a tumor bud count (Figure 1). The total number of tumor 
buds per tumor section varied considerably from patient to 
patient (Figure 2A).
Evaluation of the optimal number of cells in a 
tumor bud to use to maximize prognostic ability
We evaluated how the prognostic ability of the 
DTBC changed when tumor buds were defined as areas 
with between 1 and 20 cells (Figure 2B). We observed 
that the prognostic value of the DTBC decreased linearly 
as the tumor island area increased (Figure 2B and 
Supplementary Figure 2), suggesting that only small 
tumor islands have prognostic value. Use of a cut-off of 
950 μm2, which corresponds to fewer than six tumor cells, 
was a reasonable compromise between predictive ability, 
significance, and robustness; we therefore proceeded to 
use this cut-off value in the subsequent analyses (Figure 
2B and Supplementary Figure 2). All steps of the analysis 
were performed blinded.
Relationship between the digital tumor bud 
count and survival
We observed that the DTBC, which was divided into 
tertiles for illustrative purposes, was a significant predictor 
for OS (Figure 2C) and PFS (Figure 2D, Table 2). Of the 
prognostic factors that we tested, the DTBC was the best 
for identifying patients with a poor OS and PFS (Table 2). 
The DTBC was also a strong predictor of poor survival 
when used as a continuous variable (data not shown), 
which suggests a dose-response type relationship between 
the DTBC and poorer survival.
To test whether DTBC was independently 
related to OS or PFS, we performed a multivariate 
Cox regression analysis with conditional forward 
elimination. We observed that the DTBC was a better 
predictor of overall survival than the other variables 
from Table 2, which included absolute invasive depth 
and lymph node metastases. In fact, only DTBC, lymph 
node metastases, and age at diagnosis were independent 
factors for OS (Table 3). We performed correlation 
analyses to better characterize why only these specific 
variables were independently related to survival 
(Supplementary Figure 1).
Construction of a clinically relevant model for 
predicting lymph node metastases
None of the variables in Table 2 was, on its own, 
a strong predictor of lymph node metastases (data not 
shown). We therefore constructed a multivariate model 
to predict lymph node metastases using variables from 
Table 2 (Supplementary Materials and Methods). The 
multivariate model was able to predict lymph node 
metastases with an area under the curve (AUC) of 0.83 
(95% CI: 0.78–0.89, P <0.001, Figure 3A and variables 
are shown Supplementary Table 1) compared to an AUC 
of 0.63 (95% CI: 0.55–0.71, P=0.001) using invasive 
tumor depth as a continuous variable (Figure 3A). To 
evaluate the robustness of the multivariate model, we 
performed 10-fold cross-validation of the model and 
found a cross-validated AUC of 0.79 (95% CI: 0.73–0.85) 
(Supplementary Materials and Methods).
To better translate the findings from the model to a 
clinically meaningful decision tool, we performed decision 
curve analyses and included known clinical parameters, 
such as absolute invasive depth, for comparison (Figure 3). 
The decision curve analysis allows a clinician to evaluate 
the net benefit of different variables based on a threshold 
probability of having lymph node metastases compared 
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to no intervention or neck dissection (Figure 3C). This 
analysis demonstrated that if a clinician performed a neck 
dissection based on an 8% probability of having lymph 
node metastases, the net benefit of the final model would 
be markedly better than relying on absolute invasive depth 
(Figure 3). In addition, at a 10% probability threshold, the 
model would result in a net benefit comparable to that of 
performing SNB (Figure 3). In other words, if use of the 
model is compared to no neck dissection for anyone, then 
performing neck dissection on the basis of the model is the 
equivalent of a strategy that finds 27 occult lymph node 
metastases per hundred patients without conducting any 
unnecessary neck dissections. Another way of looking at 
the decision curve analysis is to examine the number of 
unnecessary neck dissections that would be avoided if the 
model were used compared to the option of treating all 
patients with neck dissections. At a threshold probability of 
10%, the net reduction in unnecessary neck dissections per 
100 patients is 13 using the final model compared to 0 using 
tumor depth without missing any lymph node metastases.
Table 1: Clinicopathological characteristics
No. %
Gender (Male) 126 57
Tumor site
 Floor of the mouth 103 47
 Oral tongue 94 42
 Other subsitesa 25 11
UICC Stageb
 I 111 50
 II 48 22
 III 44 20
 IVa 19 8
Tumor invasive depth
 <4mm 114 52
 >4mm 105 48
Differentiation grade
 High 57 15
 Moderate 128 59
 Poor 32 26
Tumor invasive front
 Cohesive 83 40
 Non-cohesive 123 60
Perineural invasion
 Yes 61 29
 No 150 71
Metastasesc
 N- 147 66
 N+ 75 34
Smokingd
 High 144 78
 Low 40 22
a: This category includes other oral subsites such as buccal mucosa and retromolar trigone. 
b:  The UICC stage after primary surgical treatment and pathological examination.
 Abbreviation: UICC, Union for International Cancer Control.
c:  Both the patients diagnosed with lymph node metastases from the primary surgical treatment and patients with isolated 
lymph node recurrences were considered N+.
d:  Tobacco consumption was defined as high if the patient reported a history of >10 pack-years and as low if it was ≤ 10 
pack-years. 
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DISCUSSION
This study had three major findings. First, it 
demonstrated that it is possible to obtain a clinically useful 
DTBC using a simple, semi-automatic, digital image 
analysis of AE1/AE3 cytokeratin-stained sections, which 
helps facilitate the translation of the DTBC to clinical 
practice. Second, it demonstrated that the DTBC is the 
most powerful prognostic factor in patients with early-
stage oral cancer; in fact, this parameter outperformed 
known clinical risk factors, such as the presence of lymph 
node metastases and absolute invasive tumor depth. Third, 
this study demonstrated the development and use of a 
clinically relevant risk model for lymph node metastasis 
that incorporates the tumor bud count. Most notably, this 
model has a markedly higher net benefit than absolute 
invasive depth, and its use would lead to fewer OSCC 
patients with a cN0 neck receiving unnecessary neck 
dissections.
Even though a high tumor bud count has been 
recognized as an important adverse prognostic factor, 
primarily in colorectal cancer [21] but also in several other 
cancer types including OSCC [17, 22–24], tumor budding 
is not a routine part of pathology reports. We suggest that 
the major reasons for this lack of clinical translation are 
1) the many different tumor budding scoring methods 
[25]; and 2) the time-consuming nature of counting tumor 
buds routinely in a pathology department. Tumor bud 
scoring varies considerably both in terms of which stain 
is used and in terms of the cut-off value that is used to 
determine whether the tumor bud count is high [13, 14, 24, 
26]. Furthermore, the location of the buds (intratumoral 
budding [27] vs. budding at the invasive front [28]) and 
the area that is scored (one high-power field [14] or ten 
high-power fields [29]) have varied as well, leading to a 
lack of consensus about the best method(s) to use.
We chose to use a cut-off of an area corresponding 
to five cells to define a tumor bud in this study. Although 
this cut-off is somewhat arbitrary, since no studies have 
evaluated whether other cut-offs would result in better 
predictive ability, this has been the most consistently used 
cut-off in the literature. However, we demonstrated that 
the predictive ability of the tumor bud count decreased 
linearly as the size of tumor buds decreased. In addition, 
Figure 1: Digital image analysis. An example of the digital image analysis. All brown colors, i.e. positively stained areas, were 
identified and covered with a unique label (blue). The area of each classified tumor island (blue label) was subsequently calculated. If the 
size of an individual tumor island was less than 950 μm2 they were counted as tumor buds, i.e. the Digital Tumor Bud Count (DTBC). A. 
An overview of the scanned tumor slide showing the region of interest (ROI, blue line). The yellow lines in the center of the tumor are 
necrotic areas, which were marked with another ROI and not analyzed by the software. B. As in (A), post image analysis illustrating the 
classified image where the blue area corresponds to the identified tumor area. C, D and E. represent the enlarged area of the red box in A 
and B. D: labeled areas after classification of the tumor tissue by the pre-adjusted threshold. Black arrowhead indicates a minor staining 
artefact that was unlabeled (see E) since it was < 150 μm2. E: Black arrows: Examples of tumor buds with a surface area of < 950μm2 (890 
μm2 and 885μm2 for the left and right, respectively) surrounded by a reactive stroma. The middle tumor island in (E) was 1297 μm2 and 
was therefore not counted as a tumor bud.
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Figure 2: The frequency and survival analyses of the digital tumor bud count. A. Frequency of tumor buds in patients with 
OSCC. Note that the majority has between 0 and 1000 buds per section. B. Relationship between the size of tumor bud area (i.e. estimated 
number of cell per tumor island) and the relationship with overall survival per tertile increment. There is a significant linear relationship 
between the size of the tumor buds and prognostic importance; as the islands of the tumor buds increases its importance in predicting 
survival diminishes significantly. C. Relationship between the Digital Tumor Bud Count (DTBC) and overall survival. The DTBC has been 
divided into upper, middle and lower tertiles, and the comparison is significant (P < 0.01). D. Relationship between the DTBC, divided into 
tertiles, and progression-free survival, and the comparison is significant (P < 0.01). Notice that almost none of the patients with a DTBC 
in the lower tertile have a progression after 5 years; 95% are without progression. In C and D: the numbers of patients at risk are shown at 
the time of 0, 1, 3, and 5 years.
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Table 2: Univariate analysis of pathological characteristics impact on overall and progression-free survival
Variables Overall survival Progression-free survival
Events HR (95% CI) P Events HR (95% CI) P
DTBC 64 41
 Lower tertile 9 1 4 1
 Intermediate tertile 26 3.0 (1.4-6.5) 0.004 15 4.0 (1.3-12.1) 0.01
 Upper tertile 29 4.0 (1.9-8.4) <0.001 22 7.1 (2.4-20.5) <0.001
Lymph node metastasesa 67 49
 None 36 1 25 1
 Micrometastases and ITC 7 1.7 (0.7-3.8) 0.2 6 2.0 (0.8-4.8) 0.1
 Macrometastases 24 3.8 (2.2-6.4) <0.001 15 3.1 (1.6-5.8) 0.001
Differentiation grade 66 45
 Well 14 1 8 1
 Moderate 39 1.6 (0.9-3.0) 0.1 27 2.1 (1.3-3.6) 0.004
 Poor 13 2.1 (1.0-4.5) 0.06 10 2.7 (1.5-4.9) 0.001
Absolute invasive depth 65 1.1 (1.0-1.2) 0.004 46 1.1 (1.0-1.2) 0.008
Invasive depth
 (>4 mm vs. <4 mm)
65 1.6 (1.0-2.5) 0.08 46 1.6 (0.9-3.0) 0.09
Stage (cT2 vs. cT1) 67 1.7 (1.0-2.7) 0.04 46 2.5 (1.4-4.4) 0.002
Tumor invasive front
(Non-cohesive vs cohesive)
64 1.8 (1.1-3.0) 0.03 43 2.1 (1.1-4.2) 0.03
Perineural invasion
 (yes vs. no)
64 1.7 (1.0-2.9) 0.05 43 2.2 (1.2-4.0) 0.01
Tumor location 67 46
 Floor of the mouth 28 1 22 1
 Tongue 28 1.2 (0.7-2.0) 0.5 17 0.9 (0.5-1.7) 0.7
 Other sub-sites 11 1.9 (0.9-3.8) 0.07 7 1.6 (0.7-3.8) 0.3
Age (per 1 year increment) 67 1.0 (1.0-1.1) 0.005 46 1.0 (1.0-1.0) 0.7
Smokingb (high vs. low) 58 1.5 (0.8-3.1) 0.2 41 0.8 (0.4-1.7) 0.6
Gender (male vs. female) 67 1.0 (0.6-1.6) 1 46 1.5 (0.8-2.6) 0.2
a: The size of the lymph node metastases found during primary surgical treatment.
b: Tobacco consumption was defined as high if the patient reported a history of >10 pack-years and as low if it was ≤ 10 
pack-years.
Abbreviations: DTBC, Digital Tumor Bud Count, HR, hazard ratio, CI, confidence interval, ITC, isolated tumor cells.
Table 3: Independent factors from the multivariate Cox regression analyses
Multivariate Cox regression HR (95% CI) P
Overall survival
DTBC (per tertile increase) 1.6 (1.1-2.2) 0.01
Lymph node metastasesa 1.7 (1.3-2.2) <0.001
Age at diagnosis (per 1 year increment) 1.0 (1.0-1.1) 0.007
Progression-free survival
DTBC (per tertile increase) 2.3 (1.5-3.8) <0.001
Lymph node metastasesb 1.5 (1.1-2.2) 0.01
a:  The hazard ratio for lymph node metastases represents an increase in size from no metastases to macrometastases as seen 
in Table 2.
Abbreviations: HR, hazard ratio, DTBC, Digital tumor bud count.
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we showed that the 5-cell cut-off was reasonable when 
analyzing the impact on OS.
Our proposed DTBC is relatively easy to use, 
and it has clinical relevance for both prognosis and for 
the ability to predict lymph node metastases. We thus 
propose prospectively validating our scoring method, 
which could aid in a standardization of the tumor bud 
count method. The implementation of a new, important 
risk factor is particularly relevant in OSCC, where no 
clinically useful risk factors have been implemented into 
clinical practice in recent years. Even more sophisticated 
pathological scoring methods than the DTBC have 
been advocated, such as a phosphohistone H3 and KI67 
scoring system that are proposed for use in breast cancer 
[30] and melanoma [31]. Our proposed scoring method 
makes it possible to perform all of the analyses using the 
software, except for the initial manual delineation of the 
tumor area. Therefore, the pathologist’s labor needed to 
obtain a DTBC is minor compared to the quantitative 
and standardized outcome. We acknowledge that the 
pathologist would need to identify the tumor block 
containing the deepest invasion as well as manually 
drawing a region of interest in the software in order to 
run the automated algorithm. This should however be 
compared to the labor and expense involved in step-serial 
sectioning of sentinel nodes currently performed in many 
centers. We also acknowledge that the proposed biomarker 
would only be possible to implement in a fully equipped 
digital pathology lab, which is however becoming more 
common across centers.
Figure 3: Evaluation of the predictive model and decision curve analysis. A. Receiver operating curve demonstrating the 
difference in discriminating between patients with and without occult lymph node metastases based on the final predictive model or 
tumor depth. The final model is significantly better at discrimination than using tumor invasive depth as a marker. B. Calibration plot of 
the final model showing good agreement between observed and predicted probabilities (P = 0.4, Hosmer-Lemeshow goodness-of-fit). C. 
Decision curve analysis demonstrating the net benefit associated with performing neck dissection based on the markers listed in the figure. 
Threshold probability is the specific probability of having occult lymph node metastases at which a clinician would choose to perform a 
neck dissection. The highest curve at any given threshold is the optimal decision-making strategy to maximize net benefit. D. Decision 
curve analysis demonstrating the net reduction in performing neck dissections based on the markers listed in the figure. In the range of 
relevant threshold probabilities the final model leads to a large reduction in unnecessary neck dissections compared to using tumor depth to 
evaluate presence of lymph node metastases.
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At many centers, the decision to perform neck 
dissection is currently based upon SNB results [32]. 
A recent large randomized study demonstrated better 
survival in patients that are treated with an upfront neck 
dissection as opposed to treating neck recurrence [5], 
which underlines the importance of correct staging of 
the neck at diagnosis. However, it is well known that a 
treatment algorithm that offers all patients an upfront neck 
dissection will lead to overtreatment of approximately 
70% of patients, i.e. will have a low net benefit. Since 
it is not possible to perform SNB in all head and neck 
cancer centers, other risk factors for harboring lymph 
node metastases have been proposed that are based on 
both clinicopathological characteristics and on gene 
expression studies [6]. The absolute invasive depth of 
the tumor is one of the most widely used risk factors in 
clinical use for helping decide whether a neck dissection 
should be performed [33]. It has thus been suggested that 
a depth greater than 4 mm should be used as a guide for 
choosing whether to perform a neck dissection [18, 34, 
35]. We demonstrated that the net benefit is lower when 
using absolute tumor depth (at a cut-off of 4 mm) to 
predict lymph node metastases versus using our proposed 
model, which incorporates the tumor bud count. In fact, 
the benefit of using the DTBC model may be similar to 
the benefit of using SNB at a low threshold probability of 
having lymph node metastases, but it requires a two-step 
procedure. It is also important to acknowledge that even 
SNB, apart from being both labor intensive and expensive, 
is not 100% accurate in predicting lymph node metastases 
[36]. A limitation of our study is that the DTBC needs to 
be performed on immunohistochemically stained surgical 
resection specimens, as it is not possible for the software 
to perform the analysis on standard H&E stained sections. 
The use of immunohistochemical staining in oral resection 
specimens is currently not routinely performed on oral 
cancer specimens. Additionally, it would not be possible 
to identify patients with a high risk of having lymph node 
metastases until after the primary surgery, leading to a 
two-stage procedure. This is however also the case with 
the current SNB technique.
The decision to offer adjunctive radiotherapy to 
patients with early-stage oral cancer is currently based 
primarily upon whether free margins are attained and 
whether there is extracapsular spread in any lymph node 
metastasis [3, 4]. It is therefore interesting that the DTBC 
was the most important predictor of poor survival in 
this cohort of patients with early-stage oral cancer who 
are generally considered to have overall good survival. 
The relevance of the tumor bud count in predicting 
survival was even better than the presence of lymph 
node metastases, which is currently considered the most 
important risk factor for survival in early-stage oral cancer 
and which is known to decrease survival by up to 50% 
[37, 38]. Therefore, identification of a valuable new risk 
marker in early-stage oral cancer could be relevant in 
deciding which patients with an expected poor prognosis 
should be offered adjunctive radiotherapy in the future. 
This needs to be studied in a controlled trial.
In conclusion, this study demonstrated the feasibility 
of using digital image analysis to obtain a digital tumor 
bud count from cytokeratin-stained sections from patients 
with early-stage oral cancer. This has important prognostic 
implications as the method could be used as a guide for 
choosing whether to perform neck dissection.
MATERIALS AND METHODS
Patients
We used the Reporting Recommendation for Tumor 
Marker (REMARK) guidelines to conduct and report this 
study [39]. This cohort has been described previously and 
includes 253 consecutive treatment-naïve patients with 
cT1–T2N0 OSCC who were treated at our center from 
April 2007 to December 2013 [3]. All patients were treated 
with curative intent and underwent SNB. Histological 
diagnosis of each tumor was based on examination of a 
hematoxylin and eosin (H&E) stained tissue section by 
a consultant head and neck pathologist in accordance 
with the WHO classification of tumors [40]. The TNM 
classification followed the International Union Against 
Cancer, sixth edition 2002 guidelines [41].
From the original tumor sections from the surgical 
resection specimen, which were routinely H&E stained, 
a consultant head and neck pathologist (G.L.) identified 
the tumor block with the deepest invasion for subsequent 
immunohistochemistry (IHC). IHC staining broad-
spectrum cytokeratin was performed on serial sections 
(Supplementary Methods). Formalin-fixed paraffin-
embedded (FFPE) tumor tissue was available from 222 
of the 253 patients (88 %), since the non-available tumor 
tissues had been used for other scientific studies or no 
spare unstained tissue were left. This left 222 patients 
for inclusion in the digital image analysis investigation. 
The Scientific Ethics Committee of the Capital Region of 
Denmark and the Data Protection Authority approved this 
study (ID No. H-1-2014-H53).
Scanning and digital image analysis
The cytokeratin-stained slides were scanned using 
the Axio Scan Z1 (Carl Zeiss A/S, Birkeroed, Denmark) 
at 20x magnification; the same standard scanning protocol 
was used for all samples, and images were subsequently 
checked manually to ensure good quality images. Slides 
were rescanned if necessary to ensure high image quality. 
The digital images were analyzed using Visiopharm® 
image analysis software (Visiopharm A/S, Hoersholm, 
Denmark) using a dedicated image analysis module. Since 
the anti-cytokeratin antibody also stained salivary glands, it 
was necessary to manually delineate the tumor as a region 
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of interest (ROI; performed by N.J.P. and D.H.J) in order to 
exclude salivary glands and necrotic tumor areas that could 
be misinterpreted by the software. The software identified 
areas that were positively stained for cytokeratin by setting 
a minimum threshold of differences in contrast for the 
brown signal (3,3’-diaminobenzidine, DAB) at a level 
at which the stained areas were clearly distinct from the 
non-stained areas. This part of the analysis was performed 
using 5x magnification and the same protocol was applied 
to all scans. Each independent stained area in the ROI was 
subsequently marked with a unique digital label by the 
Visopharm software (Figure 1). Labeled areas less than 
150μm2 were unlabeled by the software in order to avoid 
artefacts. Each digitally labeled area was subsequently 
quantified automatically in μm2 by the software, and this 
information recorded and stored separately for each label. 
These labels, which represented cross-sectioned tumor 
tissue, were defined as tumor buds when their area was 
below a certain size, and the total number of these labels 
were counted per slide and was considered to be the DTBC 
(Figure 1 and Supplementary Materials and Methods).
For translational purposes, we estimated the 
number of tumor cells in separate tumor buds by defining 
the average cross-section area of a single OSCC cell in 
a histological slide to be 190 μm2. As tumor buds are 
defined as tumor islands with up to 5 cells, the tumor bud 
count was subsequently calculated by counting all labels 
with a size of up to 5 × 190 μm2 = 950 μm2; the number 
of unique areas under 950 μm2 defined the DTBC. See 
Supplementary Materials and Methods for further details.
Statistical analysis
Statistical analyses were performed using 
SPSS version 22 (SPSS Inc., Chicago, IL, USA) and 
R statistics version 3.0.3 [42, 43]. The endpoints in 
the survival analyses were overall survival (OS) and 
progression-free survival (PFS) [44]. Recurrence 
at T-site was defined as a new OSCC tumor within 
2 cm of the primary OSCC tumor and histological 
verified within three years since the primary diagnosis, 
as previously described [45]. P-value <0.05 was 
considered significant. The detailed methods used 
for the statistical analyses are described in the 
Supplementary Materials and Methods.
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